ARROWHEAD PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 10, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 5. OTHER INFORMATION
(c)Trading Plans
During the quarter ended December 31, 2024, no director or officer (as defined in Exchange Act Rule 16a-1(f)) adopted or terminated trading plans intended to satisfy Rule 10b5-1(c), except as set forth in the following table:
| Name | Title | Adoption or Termination Date | Plan Start Date | Plan End Date | SharesVesting andSubject toSell-To-Cover (1) | OtherSharesBeing Sold(Subject toCertainConditions) |
|---|---|---|---|---|---|---|
| James Hamilton | Chief of Discovery and Translational Medicine | Terminated on 10/18/24 | 12/4/2024 | 11/28/2025 | n/a | 30,000 |
(1) This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold. The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.